Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hormonal influences, both natural and iatrogenic, are implicated in the most frequent health issues of women. Endometrial cancer is now the most common gynecologic cancer in the United States and the industrialized world. This cancer is strongly related to hormonal and metabolic factors. In addition, breast cancer treated with hormone therapy (Tamoxifen) may, in some cases, be associated with uterine pathology. Hormone therapy is used to improve the physiological effects and counteract abnormal and deleterious effects of “natural” hormonal activity. Millions of women receive hormone therapy at…mehr
Hormonal influences, both natural and iatrogenic, are implicated in the most frequent health issues of women. Endometrial cancer is now the most common gynecologic cancer in the United States and the industrialized world. This cancer is strongly related to hormonal and metabolic factors. In addition, breast cancer treated with hormone therapy (Tamoxifen) may, in some cases, be associated with uterine pathology. Hormone therapy is used to improve the physiological effects and counteract abnormal and deleterious effects of “natural” hormonal activity. Millions of women receive hormone therapy at some point of their life: using oral contraceptives, reproductive technology, treatment for post-menopausal symptoms, among other uses.
This book addresses a range of women’s health issues, from fertility to neoplasms, and their relationship with natural and iatrogenic hormonal effects. Chapters include clinical and pathological descriptions, theoretical and practical medical issues, and original studies and cases. Controversial issues in certain hormone therapies are presented with updated concepts based on clinical studies and novel statistical methods. The book will be useful for specialized and general physicians, oncologists, endocrinologists, researchers, medical students, and others in the field of women’s health.
Dr. Liane Deligdisch-Schor graduated from Medical School in Bucarest, Romania, trained in Obstetrics-Gynecology and Pathology in Romania, then specializing in Gynecologic Pathology at the Magee Womens Hospital in Pittsburgh, Pa. and at the Free Hospital for Women, Harvard Medical School, Boston Mass. She founded the Division of Gynecologic Pathology and the course of Gynecologic Pathology at the Mount Sinai School of Medicine in New York where she is a tenured Professor since 1986 and Professor Emeritus since 2016, devoting her time to diagnosis, teaching and research activities. She was elected a member of the French National Academy of Medicine in 2007; authored over 150 peer reviewed articles and edited 7 textbooks, with the main topics early detection of neoplasms of the female genital tract and Hormonal Pathology of the Uterus. In addition to numerous case reports her publications include extensive studies of Ovarian Cancer precursors, with Histopathologic changes correlated to Computerized Image Analysis and Molecular Studies, being the first in the medical literature to describe Ovarian Dysplasia. Numerous clinical-histopathologic studies of hormonal Pathology of the Uterus included ultrastructural and morphometric changes and viral DNA studies correlated to clinical aspects of Endometrial neoplastic lesions. Dr. Liane Deligdisch-Schor received numerous awards for teaching and research and is often invited as keynote speaker at national and international meetings. She is also an enthusiastic art lover and traveler.
Dr. Angelica Mareş Miceli graduated from Medical School in Bucharest, Romania, trained in Pathology in Bucharest and New York, then specialized in Gynecologic Pathology and Cytopathology at Mount Sinai Hospital in New York, under the mentorship of Dr Liane Deligdisch-Schor. Their research collaboration started more than fifteen years ago. Presently, Dr Mareş Miceli works in the field of GynecologicPathology and teaching in Pathology/ Pathophysiology Program at New York Medical College – School of Medicine. Her work includes diagnosis, clinical-pathologic correlation, teaching students and pathology residents, research on ovarian dysplasia and carcinoid ovarian tumors, and publishing; her interests are early diagnosis and the study of cancer precursors in gynecologic neoplasms, pediatric, adolescent and young adult gynecology. Dr. Mareş Miceli is involved in many academic activities, being a member in numerous committees for education and curriculum, promotions and career advisor; she received many awards for teaching and is often invited as speaker at national and international meetings. She is also an enthusiastic nature and art lover.
Inhaltsangabe
1. Biophysiology of the uterus: development, cyclic changes, menopause.- 2. Hormonal effects in reproductive technology (ovulation stimulation, in vitro fertilization).- 3. Hormonal role and therapy in common benign uterine lesions: endometrial polyps, leiomyomas, adenomyosis.- 4. Endometrial hyperplasia; precancerous lesions of the endometrium. Hormone therapy.- 5. Endometrial Carcinoma. Endometriosis, Hormonal Role in Carcinogenesis. Hormonal Therapy.- 6. Menopausal Hormone Therapy. Contraceptives.- 7. Replacement hormone therapy for gender dysphoria and congenital sexual anomalies.- 8. Hormone therapy for endometrial neoplasia related to breast cancer therapy (Tamoxifen).- 9. Endometrial histopatholigic changes in hormonal therapy (contraceptives, ovulation stimulation, hormone replacement therapy, hormonal antitumoral therapy).
1. Biophysiology of the uterus: development, cyclic changes, menopause.- 2. Hormonal effects in reproductive technology (ovulation stimulation, in vitro fertilization).- 3. Hormonal role and therapy in common benign uterine lesions: endometrial polyps, leiomyomas, adenomyosis.- 4. Endometrial hyperplasia; precancerous lesions of the endometrium. Hormone therapy.- 5. Endometrial Carcinoma. Endometriosis, Hormonal Role in Carcinogenesis. Hormonal Therapy.- 6. Menopausal Hormone Therapy. Contraceptives.- 7. Replacement hormone therapy for gender dysphoria and congenital sexual anomalies.- 8. Hormone therapy for endometrial neoplasia related to breast cancer therapy (Tamoxifen).- 9. Endometrial histopatholigic changes in hormonal therapy (contraceptives, ovulation stimulation, hormone replacement therapy, hormonal antitumoral therapy).
1. Biophysiology of the uterus: development, cyclic changes, menopause.- 2. Hormonal effects in reproductive technology (ovulation stimulation, in vitro fertilization).- 3. Hormonal role and therapy in common benign uterine lesions: endometrial polyps, leiomyomas, adenomyosis.- 4. Endometrial hyperplasia; precancerous lesions of the endometrium. Hormone therapy.- 5. Endometrial Carcinoma. Endometriosis, Hormonal Role in Carcinogenesis. Hormonal Therapy.- 6. Menopausal Hormone Therapy. Contraceptives.- 7. Replacement hormone therapy for gender dysphoria and congenital sexual anomalies.- 8. Hormone therapy for endometrial neoplasia related to breast cancer therapy (Tamoxifen).- 9. Endometrial histopatholigic changes in hormonal therapy (contraceptives, ovulation stimulation, hormone replacement therapy, hormonal antitumoral therapy).
1. Biophysiology of the uterus: development, cyclic changes, menopause.- 2. Hormonal effects in reproductive technology (ovulation stimulation, in vitro fertilization).- 3. Hormonal role and therapy in common benign uterine lesions: endometrial polyps, leiomyomas, adenomyosis.- 4. Endometrial hyperplasia; precancerous lesions of the endometrium. Hormone therapy.- 5. Endometrial Carcinoma. Endometriosis, Hormonal Role in Carcinogenesis. Hormonal Therapy.- 6. Menopausal Hormone Therapy. Contraceptives.- 7. Replacement hormone therapy for gender dysphoria and congenital sexual anomalies.- 8. Hormone therapy for endometrial neoplasia related to breast cancer therapy (Tamoxifen).- 9. Endometrial histopatholigic changes in hormonal therapy (contraceptives, ovulation stimulation, hormone replacement therapy, hormonal antitumoral therapy).
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der Steintor 70. V V GmbH (zukünftig firmierend: buecher.de internetstores GmbH)
Geschäftsführung: Monica Sawhney | Roland Kölbl
Sitz der Gesellschaft: Hannover
Amtsgericht Hannover HRB 227001
Steuernummer: 321/neu